CD274 and esophageal squamous cell carcinoma: IO is highly effective in the second-line treatment for ESCC in patients with high PD-L1 (CPS ≥10) expression, offering OS and PFS benefit as well as statistically significantly higher response rates, and this was confirmed in our pooled analysis.